Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy

At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form […]

Continue Reading

Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology

Merck, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. “This agreement is another illustration of how we aim to enrich our discovery engine with […]

Continue Reading

Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW

Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas with the potential to complement – or even positively disrupt – established approaches to driving access to healthcare. The three winners, chosen from over 400 […]

Continue Reading

Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition

The Bayer Cares Foundation recently presented the 2018 Aspirin Social Innovation Awards to five international initiatives for their groundbreaking ideas in the fields of healthcare and nutrition. The award-winners are all impact pioneers whose concepts have the potential to bring about sustainable, systematic changes to thus improve the living conditions of hundreds of millions of […]

Continue Reading

Brilinta’s Phase III THEMIS trial met primary endpoint in 
patients with established coronary artery disease and type-2 diabetes

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior […]

Continue Reading